GRI-152: A Non-Specific Subtype of Glutamate Receptor Ionotropic

Target Name: Glutamate Receptor Ionotropic

NCBI ID: P12941

Glutamate Receptor Ionotropic

Other Name(s): Ionotropic glutamate receptor | iGluR | Glutamate Receptor Ionotropic

GRI-152: A Non-Specific Subtype of Glutamate Receptor Ionotropic

The Glutamate Receptor Ionotropic (nonspecified subtype), also known as GRI-152, is a protein that is expressed in various tissues throughout the body, including the brain, nervous system, and heart. It plays a crucial role in the regulation of ion channels , which are responsible for the flow of electrical signals in the nervous system.

GRI-152 is a member of the Glutamate Receptor family, which includes several different subtypes that are involved in the regulation of ion channels. The GRI-152 subtype is a non-specific subtype of the Glutamate Receptor ionotropic subtype, which is characterized by the presence of a unique transmembrane domain and a unique extracellular loop.

The GRI-152 subtype is expressed in a variety of tissues and is involved in the regulation of a wide range of physiological processes, including neurotransmitter signaling, muscle contractions, and heart rate. It is also involved in the regulation of ion channels, which are critical for the flow of electrical signals in the nervous system.

One of the key functions of GRI-152 is its role in the regulation of action potentials, which are the fundamental units of electrical activity that are generated by the discharge of ions through ion channels. GRI-152 is involved in the regulation of the height and duration of action potentials, as well as the regulation of the spread of electrical activity across the cell membrane.

In addition to its role in the regulation of action potentials, GRI-152 is also involved in the regulation of other physiological processes that are critical for the maintenance of normal brain function. For example, it is involved in the regulation of neurotransmitter release from nerve Yuan, which is critical for the transmission of signals throughout the nervous system.

GRI-152 is also involved in the regulation of muscle contractions, which are critical for movement and maintaining posture. It is also involved in the regulation of heart rate, which is critical for maintaining blood pressure and circulating blood throughout the body.

GRI-152 is a potential drug target, as it is involved in a wide range of physiological processes that are critical for human health and wellbeing. Studies have suggested that GRI-152 may be a useful target for the development of new treatments for a variety of neurological and psychiatric disorders, including epilepsy, schizophrenia, and depression.

In conclusion, GRI-152 is a non-specific subtype of the Glutamate Receptor ionotropic subtype that is involved in the regulation of a wide range of physiological processes. It is a potential drug target, as it is involved in a variety of important physiological processes that are critical for human health and wellbeing. Further research is needed to fully understand the role of GRI-152 in the regulation of ion channels and its potential as a drug target.

Protein Name: Glutamate Receptor Ionotropic (nonspecified Subtype)

The "Glutamate Receptor Ionotropic Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Glutamate Receptor Ionotropic comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets